😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

Horizon tumbles on potential FTC lawsuit to block Amgen deal; analysts surprised

Published 16-05-2023, 04:22 pm
© Reuters.

Bloomberg News reported yesterday that the U.S. Federal Trade Commission (FTC) is expected to introduce a lawsuit to block the proposed merger between Amgen (NASDAQ:AMGN) and Horizon Therapeutics (NASDAQ:HZNP).

The FTC is reportedly worried by the portfolio overlap as both businesses are working on treatments for Lupus and Eczema. Hence, the merger would harm the development of drugs in these areas.

Amgen agreed to pay $27.8 billion to buy Horizon. If the lawsuit is launched, Wells Fargo analysts believe the remedy could be divestiture of the Horizon pipeline as Amgen’s key focus is likely on the marketed products.

“While AMGN and HZNP marketed products do not overlap, recent FTC scrutiny seems to be pushing it a bit further than traditional overlapping markets and investigating if a single player is becoming stronger. Our look at recent instances of FTC lawsuit suggests that 3/6 such deals were either terminated/blocked while other 3 went through,” the analysts said in a client note.

They believe Amgen shares could receive a boost if the deal fails to go through as shareholders mostly didn’t like the deal.

On the other hand, the analysts note that Horizon shares could fall to the $80-90 range. Horizon stock is indicated to open at ~$93 a share, down about 17% in premarket Tuesday.

BMO analysts said investors may become more nervous as Bloomberg’s reporting signals the FTC may be focused on challenging bigger pharma deals.

“If this signals FTC’s view around the broader anticompetitive nature of pharmaceutical mergers, then we could see a potential challenge [to larger transactions],” they said in a note.

RBC analysts are surprised by the potential lawsuit as they see “the minimal portfolio overlap” while potential fold-in assets with AMGN present “minimal concerns of harm or competitiveness to the landscape.”

“We – and inbound investors – have seen a high likelihood of close,” they wrote.

Horizon shares were down 1.3% year-to-day through Monday’s close.


Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.